Structured Abstract

Contents

• Errata
• Preface
• Acknowledgments
• Technical Expert Panel
• Peer Reviewers
• Executive Summary
• Introduction
  • Schizophrenia and Related Psychoses
  • Bipolar Disorder
  • Key Questions
• Methods
  • Topic Refinement and Technical Expert Panel
  • Literature Search Strategy
  • Criteria for Study Selection
  • Assessment of Methodological Quality
  • Data Extraction
  • Data Analysis
  • Grading the Strength of a Body of Evidence
  • Applicability
• Results
  • Literature Search
  • Description of Included Studies
  • Methodological Quality of Included Studies
  • Schizophrenia (Key Questions 1, 2, 4, 5)
  • Bipolar Disorder (Key Questions 1, 2, 4, 5)
  • Adverse Events (Key Question 3)
• Summary and Discussion
  • Key Question 1 Core Illness Symptoms
  • Key Question 2 Functional Outcomes and Health Care Resource Utilization
  • Key Question 3 Medication-Associated Adverse Events and Safety
  • Key Question 4 Other Outcomes
  • Key Question 5 Subgroups
  • Results in the Context of Previous Literature
  • Applicability
  • Limitation of Existing Evidence
  • Future Research
  • Conclusions
• References
• Abbreviations
• Appendix A Literature Search Strategies
• Appendix B Sample Data Extraction and Quality Assessment Forms
• Appendix C List of Excluded Studies
• Appendix D List of Companion Studies
• Appendix E Risk of Bias Assessment for Randomized Controlled Trials and Nonrandomized Controlled Trials
• Appendix F Summary Risk of Bias Assessments
• Appendix G Newcastle-Ottawa Scale Assessment of Cohort Studies
• Appendix H General Study Characteristics
• Appendix I Patient Flow Through Trials
• Appendix J Forest Plots for Adverse Events
• Appendix K Funnel Plots
• Appendix L Subscales, Composite Outcomes, and Functional Capacity
• Appendix M Subgroup and Sensitivity Analyses
• Appendix N Summary Tables of Adverse Events
• Appendix O First-Generation and Second-Generation FDA-Approved and Available Antipsychotics

Prepared for: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services¹, Contract No. 290-2007-10021, Prepared by: University of Alberta Evidence-based Practice Center, Edmonton, Alberta, Canada

Suggested citation:

Abou-Setta AM, Mousavi SS, Spooner C, Schouten JR, Pasichnyk D, Armijo-Olivo S, Beaith A, Seida JC, Dursun S, Newton AS, Hartling L. First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness. Comparative Effectiveness Review No. 63. (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021.) AHRQ Publication No. 12-EHC054-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2012. www.effectivehealthcare.ahrq.gov/reports/final.cfm.

This report is based on research conducted by the University of Alberta Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10021). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.

1

540 Gaither Road, Rockville, MD 20850; www​.ahrq.gov